Logo

Silo Pharma with Sever Pharma Solutions Obtains Regulatory Approval to Conduct the Development of Ketamine Implant for Fibromyalgia

Share this
silo pharma

Silo Pharma with Sever Pharma Solutions Obtains Regulatory Approval to Conduct the Development of Ketamine Implant for Fibromyalgia

Shots:

  • Sever Pharma Solutions has obtained state and federal DEA approval to work with ketamine and load it into Silo Pharma's implant, SP-26, following positive compliance inspections
  • SP-26 is developing through analytical testing and small batch pre-clinical PoC extrusion trials to assess drug release and stability. The dosage and time-release implant formulation of SP-26 will be studied using SC injection
  • The early preclinical research for SP-26 will emphasize on the drug's safety profile, aligning with FDA requirements for potential at-home therapeutic designation. Silo also anticipates the US FDA approval through the streamlined 505(b)(2) pathway

Ref: Globe Newswire | Image: Silo Pharma

Related News:- Tonix Pharmaceuticals Reports the Results for TNX-102 SL in P-III Trial for the Management of Fibromyalgia

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions